Key points
- U.S. customers progress with Salix® platform
- Northeast Georgia Health System goes live in July
- Salix® Coronary Flow validation nears completion
- SAPPHIRE Study commences with investigator meeting
- Clinical Advisory Board formation advanced
Full summary
Artrya Limited, a medical technology company, released its June Quarterly Activities Report highlighting significant progress in commercializing its Salix® AI-powered platform for coronary artery disease assessment. U.S. customers, including Tanner Health and Northeast Georgia Health System, have progressed with platform deployment. Salix® Coronary Flow validation is nearing completion, with FDA submission imminent. The SAPPHIRE Study has commenced, and the Clinical Advisory Board formation has advanced, strengthening Artrya's U.S. clinical strategy. Financial results show a pro forma cash position of $74.0M at 30 June 2026.
Outlook
Artrya is well positioned to accelerate the commercialisation of Salix® with a strong balance sheet, expanding commercial pipeline, and increasingly repeatable deployment model.